NeuroSense Therapeutics Ltd. (NRSN) Form 6-K — Aug 13, 2026
NeuroSense Therapeutics issued a CEO letter on August 13, 2026 updating shareholders on its pivotal Phase 3 PARAGON study of PrimeC in ALS. The FDA has cleared the study, expected to enroll roughly 300 participants primarily in the United States, but the company said the financing needed to launch it has taken longer than originally anticipated. NeuroSense is pursuing financing in parallel through pharmaceutical and strategic partners, investors, grants, and other non-dilutive sources, while also exploring broader partnerships around PrimeC's development and commercialization.
Key figures
- Canada nds expected
- December 2026
- Als annual diagnoses us
- more than 5,000
- Insider investment each
- $200,000
- Phase3 enrollment target
- approximately 300 participants
- Als annual disease burden us
- $1 billion
- Insider investment aggregate
- $600,000
- Reverse split proposed range
- 1:4 to 1:40
- Als prevalence growth by 2040
- 24%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.